93. Primary biliary cholangitis Clinical trials / Disease details

Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02135536 (ClinicalTrials.gov)	May 2014	8/5/2014	Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis	A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103	Primary Biliary Cirrhosis	Biological: NGM282	NGM Biopharmaceuticals, Inc	NGM Biopharmaceuticals Australia Pty Ltd	Completed	18 Years	75 Years	All	36	Phase 2	United States;Australia;New Zealand
2	NCT02026401 (ClinicalTrials.gov)	February 2014	30/12/2013	Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis	A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis	Primary Biliary Cirrhosis	Biological: NGM282;Biological: Placebo	NGM Biopharmaceuticals, Inc	NGM Biopharmaceuticals Australia Pty Ltd	Completed	18 Years	75 Years	All	45	Phase 2	United States;Australia